Invivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 22,355 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 22,355 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $16,095.60. Following the transaction, the insider directly owned 197,362 shares in the company, valued at $142,100.64. The trade was a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, August 18th, Timothy Edward Lee sold 18,425 shares of Invivyd stock. The stock was sold at an average price of $0.84, for a total transaction of $15,477.00.

Invivyd Stock Performance

Invivyd stock opened at $0.87 on Wednesday. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07. The firm has a market cap of $255.75 million, a PE ratio of -2.63 and a beta of 0.71. The firm’s 50 day moving average price is $0.77 and its two-hundred day moving average price is $1.23.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Equities analysts anticipate that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Institutional Trading of Invivyd

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp grew its position in shares of Invivyd by 9.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock worth $139,000 after buying an additional 8,800 shares during the period. Bank of New York Mellon Corp increased its position in shares of Invivyd by 54.3% in the 1st quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock valued at $35,000 after buying an additional 9,568 shares in the last quarter. Courier Capital LLC bought a new stake in shares of Invivyd in the fourth quarter worth about $25,000. Bronte Capital Management Pty Ltd. bought a new stake in Invivyd during the 4th quarter worth approximately $27,000. Finally, DRW Securities LLC acquired a new stake in shares of Invivyd during the fourth quarter worth $27,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.